A novel copper-based nanosystem for augmented breast cancer photothermal and chemodynamic therapy Mohammad Seyedhamzeh, Farzaneh Falahi, Ali Kalantari-Hesari, Kimia Esmaeilzadeh, Laleh Salarilak, Hadi Bagheri, Shayesteh Bochani, Satar Yousefiasl, Helia Behrouzfar, Mohammad Esmaeil Akbari, Aziz Maleki Rsc Advances, 2026 This work develops and characterizes copper-cysteine nanoparticles as a multifunctional nanoplatform combining photothermal therapy and chemodynamic therapy to ablates primary tumors and inhibit metastatic breast cancer cells in tumor-bearing mice.
Protective role of fucoidan against cognitive deficits and redox imbalance in a scopolamine-induced Alzheimer’s disease model in rats Maryam Salmani, Mahdieh Anoush, Ali Kalantari-Hesari, Armin Jahani-Maleki, Fatemeh Nouri, Mir-Jamal Hosseini, Mojdeh Mohammadi Scientific Reports, 2025 This study examined the neuroprotective impacts of fucoidan on behavioral performance and oxidative damage in an animal model with scopolamine-induced cognitive deficits. Male Wistar rats, aged 8 weeks, were administered scopolamine (2 mg/kg) for 10 days. Fucoidan (15–60 mg/kg) or donepezil (1 mg/kg) was administered prior to behavioral tests over three consecutive weeks. To assess memory and learning, all rats underwent the Morris water maze (MWM) task and the Novel Object Recognition (NOR) test. Following the tests, the hippocampi and prefrontal cortex (PFC) of the rats were collected to evaluate oxidative stress parameters across all treatment groups. A significant decrease in the mean Q 2 time was observed during the probe trial in the water maze task after scopolamine injection on the test day. Administration of fucoidan (15–60 mg/kg) or donepezil (1 mg/kg) notably improved cognitive dysfunction (p < 0.001) . Biochemical analysis demonstrated a decline in protein carbonyl and malondialdehyde levels, along with an elevation in reduced glutathione and total antioxidant capacity in the fucoidan-treated rats (15–60 mg/kg). It is supposed that cholinergic dysfunction and oxidative stress are key contributors to cognitive deficits, and fucoidan may protect the hippocampus and prefrontal cortex by mitigating oxidative damage biomarkers.
Application of edaravone-loaded nanogel in alleviating behavioral deficits and oxidative stress in schizophrenia rat model Sina Montazeri, Soroush Bijani, Hamid Rashidzadeh, Ali Ramazani, Sina Andalib, Ali Kalantari-Hesari, Ghazale Cheraghi, Mir-Jamal Hosseini Scientific Reports, 2025 Schizophrenia is considered as a main one of the public health issues, and imposes numerous burdens on patients and society. We previously reported, the pathophysiology of schizophrenia is influenced by inflammation and mitochondrial dysfunction. Edaravone (EDV) as a potent antioxidant with neuroprotective traits, has been approved for the treatment of amyotrophic lateral sclerosis (ALS), effecting through neutralizing soluble/insoluble peroxyl radicals. However, the main disadvantages of EDV are its low stability in aqueous media, poor water solubility, and un-optimized bioavailability. To effectively address these obstacles, nanogel was utilized as the drug vehicle. The decoration of nanogel surface with glutathione (GSH) was carried out to elevate edaravone's brain delivery. The probable improvement in drug delivery of edaravone loaded GSH-nanogel is the main hypothesis of this study. In order to mimic schizophrenia-like behaviors, we applied two month of post-weaning social isolation stress (PWSI) to rodent model. The choice of PWSI model was made due to the maturation and development of prefrontal cortex and hippocampus during adolescence. In addition to causing oxidative stress and upregulating genes linked to innate immunity in the prefrontal cortex (PFC), the data showed that PWSI triggered schizophrenia-like behaviors in rats. This study demonstrated that treatment with edaravone loaded GSH-nanogel decreased the impact of PWSI on behavioral dysfunctions and oxidative stress in the PFC of rats. Edaravone loaded GSH-nanogel (GSH-PMAA-EDV) down-regulated Toll-like receptor 4 (Tlr-4) and AMP-activated protein kinase (Ampk) gene expression which are involved in inflammation and cellular energy homeostasis, respectively. Increase immunoreactivity feedback and Brain-derived neurotrophic factor (Bdnf) as direct impact in neurogenesis and neural cell plasticity was observed in EDV loaded GSH-nanogel treated groups. edaravone loaded GSH-nanogel (100 µg/kg) in comparison to free form of edaravone (5 mg/kg) revealed more beneficial effects, which might be useful for future clinical use especially for the treatment of schizophrenia.
Visceral leishmaniosis in dogs from western Iran Alireza Sazmand, Georgiana Deak, Ali Kalantari-Hesari, Pouria Rafiei, Navid Etemadi, Hesam Hajilou, Mina Malekmohammadi, Leili Moradi, Monireh Khordadmehr, Seyedmousa Motavallihaghi, Ali Fattahi-Bafghi, Mariaelisa Carbonara, Stephanie Oren, Domenico Otranto Veterinary Parasitology Regional Studies and Reports, 2025
Neuroprotective effects of empagliflozin against scopolamine-induced memory impairment and oxidative stress in rats Mahdieh Anoush, Neda Taghaddosi, Zahra Bokaei Hosseini, Fatemeh Rahmati, Soroush Bijani, Ali Kalantari-Hesari, Mir-Jamal Hosseini Ibro Neuroscience Reports, 2025 Alzheimer's disease (AD) is one of the most common age-related neurodegenerative disorders. The main medicinal theory for the management of AD belongs to the acetyl-cholinesterase-inhibition pathway and NMDA antagonism. Recent investigation proposed memory improvement by sodium-glucose co-transporter 2 (SGLT2) inhibitors which indicated to improve glycemic control in adults with type 2 diabetes mellitus. According to the lack of sufficient evidence about the efficacy of empagliflozin (EMPA) for memory improvement, in comparison with donepezil (DON), the present research was carried out in order to investigate this hypothesis towards scopolamine-induced neurotoxicity on experimental male Wistar rats. The animals divided into two sets, each included 4 groups: The first set of Healthy animals [Control, EMPA (4 or 10 mg/kg), DON (1 mg/kg)]. The second set of rat Alzheimer model, which received 2 mg/kg Scopolamine by intraperitoneal route for 10 days followed by other treatments [AD, AD+ EMPA (4 or 10 mg/kg) and AD+DON]. Normal rats and AD rats, with each group receiving different substances for 8 consecutive days and 24 h after the accomplishment of the drug administrations, the memory functions assessed through Morris water maze (MWM) paradigm. This task was followed by decapitation of rats in order to evaluate the biochemical oxidative stress parameters in brain tissue. Our data indicated that EMPA significantly improved animals' performance in the behavioral test with a significant decrease in oxidative stress and antioxidant imbalance. In addition, EMPA (4 mg/kg) significantly reduced both cellular malondialdehyde and protein carbonyl content while conversely increased the total reduced glutathione content. Besides, the levels of total as well as endogenous antioxidants in the ferric reducing antioxidant power assay reported to be augmented. It seems that EMPA significantly improved both cellular biochemical aspects and memory performance in animal models in accordance with histopathological assessments. Conclusively, 4 mg/kg EMPA demonstrated better results in all aspects that were evaluated during this research.
Estimating Proportion of Meat and Validating Results of Meat Products Using Histochemistry and Image Analysis in Meat Products of Hamadan City, Iran Iranian Journal of Nutrition Sciences and Food Technology, 2023
An Evaluation of the Protective Effects of Coenzyme Q10 on Fertility Parameters of Male Mice Treated with Methotrexate Journal of Babol University of Medical Sciences, 2023
Effect of Molybdenum Trioxide Nanoparticles on the Kidney in Rats Journal of Gorgan University of Medical Sciences, 2023
Dietary garlic powder supplementation could ameliorate unfavorable effects of choline deficiency on the liver health and immune system of broiler chickens Iranian Journal of Applied Animal Science, 2019